Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.
Forkhead box protein 3-positive regulatory T (Treg) cells are indispensable for the maintenance of self-tolerance and immune homeostasis. They can also be exploited for the treatment of immunologic diseases, including autoimmune diseases and allergy, by way of activating and expanding antigen-specific Treg cells in vivo. Cell therapy with in vitro activated and expanded Treg cells can be another therapeutic modality. The feasibility of such Treg cell-based therapeutic strategies is discussed based on recent advances in our understanding of the molecular and cellular basis of Treg cell development and function.
Miyara
Makoto
M
Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
Wing
Kajsa
K
Sakaguchi
Shimon
S
D000818:Animals; D015551:Autoimmunity; D016207:Cytokines / Q000502:physiology; D051858:Forkhead Transcription Factors / Q000032:analysis*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007108:Immune Tolerance; D007167:Immunotherapy; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000502:physiology
D016207:Cytokines; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D016853:Muromonab-CD3